Skip to content
10-K

Annual Report

VITRO BIOPHARMA, INC.

0001493152-24-004126

← back to feed
Filed
Jan 29, 2024 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding FY 2023 · Jan 29, 2024 4.43M sh
Shares Diluted FY 2023 · Oct 31, 2022 4.14M sh
Capex FY 2023 · Oct 31, 2022 $310.11K
Operating Cash Flow FY 2023 · Oct 31, 2022 −$2.22M
Long Term Debt FY 2023 · Oct 31, 2022 $2.67M
Current Liabilities FY 2023 · Oct 31, 2022 $2.54M
Total Liabilities FY 2023 · Oct 31, 2022 $5.74M
Current Assets FY 2023 · Oct 31, 2022 $2.94M
Total Assets FY 2023 · Oct 31, 2022 $8.57M
Eps Diluted FY 2023 · Oct 31, 2022 −$1.87
Eps Basic FY 2023 · Oct 31, 2022 −$1.87
Sga Expense FY 2023 · Oct 31, 2022 $7.6M
Rd Expense FY 2023 · Oct 31, 2022 $155.63K
Net Income FY 2023 · Oct 31, 2022 −$6.86M
Operating Income FY 2023 · Oct 31, 2022 −$5.97M
Gross Profit FY 2023 · Oct 31, 2022 $2.71M
Cost Of Revenue FY 2023 · Oct 31, 2022 $586.88K
Revenue FY 2023 · Oct 31, 2022 $3.29M
Stockholders Equity FY 2023 · Oct 31, 2021 $3.45M